Ruggeri, M., Tosetto, A., Palandri, F., et al. (2013) Thrombotic Risk in Patients with Primary Immune Thrombocytopenia Is Only Mildly Increased and Explained by Personal and Treatment-Related Risk Factors. Journal of Thrombosis and Haemostasis, 12, 1266-1273.
https://doi.org/10.1111/jth.12636

has been cited by the following article:

• TITLE: Association between Immunological Thrombocytopenia and Thrombosis, Is It an Exotic Phenomenon?—A Case Report

  AUTHORS: Mounia Salah, Siham Hamaz, Houda Bachir, Habiba Alaoui, Khalid Serraj

  KEYWORDS: Immune Thrombocytopenia, Thrombosis, Immunosuppressive Therapy, Corticosteroid Therapy, Corticosteroid Dependence

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.10 No.9, September 30, 2022

  ABSTRACT: Immunologic thrombocytopenia (ITP) is an autoimmune disease associated with the production of autoantibodies against specific platelet membrane glycoproteins. A thrombotic event as an unusual occurrence during ITP is becoming more and more frequent. In fact, several recent studies have shown an increased thrombotic risk in this situation. The case presented here is that of a fifty-one-year-old woman with extensive cerebral venous thrombosis 2 years after her ITP diagnosis. During IT, thrombosis may be triggered by the release of pro-thrombotic platelet micro-particles and by platelet activation due to the interaction between autoantibodies and platelet glycoproteins. Immunosuppressive therapy has also been linked in several studies to the thrombotic phenomenon. Increased thromboembolic risk should be taken into account in all ITP patients.